Sublingual Adjuvant Delivery by a Live Attenuated Vibrio cholerae-Based Antigen Presentation Platform by Liao, Julie et al.
Sublingual Adjuvant Delivery by a
Live Attenuated Vibrio cholerae-
Based Antigen Presentation Platform
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Liao, Julie, Jacob A. Gibson, Bradley S. Pickering, and Paula I.
Watnick. 2018. “Sublingual Adjuvant Delivery by a Live Attenuated
Vibrio cholerae-Based Antigen Presentation Platform.” mSphere




Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
Sublingual Adjuvant Delivery by a Live Attenuated Vibrio
cholerae-Based Antigen Presentation Platform
Julie Liao,a Jacob A. Gibson,a Bradley S. Pickering,b Paula I. Watnicka,c
aDivision of Infectious Diseases, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts,
USA
bNational Centre for Foreign Animal Diseases, Canadian Food Inspection Agency, Government of Canada,
Canadian Science Centre for Human and Animal Health, Winnipeg, Manitoba, Canada
cDepartment of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, USA
ABSTRACT A sublingually delivered heterologous antigen presentation platform
that does not depend on antigen or adjuvant puriﬁcation would be of great beneﬁt
in protection against diarrheal disease. In proof-of-concept studies, we previously
showed that when a fusion protein comprised of the Vibrio cholerae bioﬁlm matrix
protein RbmA and the B subunit of cholera toxin (R-CTB) is expressed from a plas-
mid within V. cholerae, R-CTB is sequestered in the bioﬁlm matrix, leading to decora-
tion of the cell surface. Sublingual delivery of live attenuated R-CTB-decorated cells
results in a mucosal immune response to CTB. To improve the immune response to
diarrheal antigens presented by this platform, we have engineered our live attenu-
ated vaccine to express the mucosal adjuvant mmCT (i.e., multiply mutated CT).
Here we report that delivery of this adjuvant via sublingual administration of our
vaccine enhances the mucosal immune response to V. cholerae LPS and elicits a sys-
temic and mucosal immune response to CTB. However, provision of R-CTB with
mmCT selectively blunts the mucosal immune response to CTB. We propose that
mmCT delivered by this live attenuated Vibrio cholerae vaccine platform may serve
as a mucosal adjuvant for heterologous antigens, provided they are not too similar
to mmCT.
IMPORTANCE Diarrheal disease is the most common infectious disease of children
in the developing world. Our goal is to develop a diarrheal antigen presentation
platform based on whole Vibrio cholerae cells that does not depend on protein puri-
ﬁcation. We have previously shown the feasibility of genetically fusing antigens to
the V. cholerae bioﬁlm matrix protein RbmA for presentation on the cell surface. A
mucosal adjuvant could improve immunogenicity of such a vaccine at the mucosal
surface. Here we engineer a live attenuated V. cholerae vaccine to constitutively syn-
thesize mmCT, a nontoxic form of cholera toxin. When this vaccine is delivered sub-
lingually, in vivo-synthesized mmCT acts as both an adjuvant and antigen. This could
greatly increase the magnitude and duration of the immune response elicited by
codelivered heterologous antigens.
KEYWORDS Vibrio cholerae, cholera toxin adjuvants, live vector vaccines, mmCT,
vaccine, vaccine platform
Diarrhea is the leading infectious disease of young children in the developing world,and yet few vaccines targeting diarrheal disease exist (1). Our goal is to develop an
antigen presentation platform for diarrheal disease that circumvents the need for
protein puriﬁcation. Vibrio cholerae is responsible for cholera, an epidemic diarrheal
disease that targets children living in temperate climates and populations displaced by
political unrest or environmental disaster, such as those in Yemen, Rwanda, and Haiti
Received 1 May 2018 Accepted 16 May
2018 Published 6 June 2018
Citation Liao J, Gibson JA, Pickering BS,
Watnick PI. 2018. Sublingual adjuvant delivery
by a live attenuated Vibrio cholerae-based
antigen presentation platform. mSphere 3:
e00245-18. https://doi.org/10.1128/mSphere
.00245-18.
Editor Drusilla L. Burns, Food and Drug
Administration
Copyright © 2018 Liao et al. This is an open-
access article distributed under the terms of
the Creative Commons Attribution 4.0
International license.
Address correspondence to Paula I. Watnick,
paula.watnick@childrens.harvard.edu.
A live attenuated Vibrio cholerae vaccine





May/June 2018 Volume 3 Issue 3 e00245-18 msphere.asm.org 1
(2–4). Both live attenuated and inactivated whole-cell vaccines that protect against
cholera have been developed and are licensed (5–7). Our laboratory has developed a
technology that can transform these live attenuated or inactivated whole-cell cholera
vaccines into vaccine platforms. This technology is based on genetic fusion of protein
antigens to the bioﬁlm matrix-associated protein RbmA (8).
Cholera toxin (CT), which produces the watery diarrhea characteristic of cholera (9),
is quite similar to the heat-labile toxin (LT) of the diarrheal pathogen enterotoxigenic
Escherichia coli (ETEC). While antilipopolysaccharide (anti-LPS) antibodies correlate most
closely with protection against cholera (10), antibodies against the B subunit of cholera
toxin (CTB) are thought to provide some protection against strains of ETEC that encode
LT (11–13). We previously showed that plasmid-based expression of a genetic fusion of
CTB to RbmA (R-CTB) resulted in abundant decoration of the cell surface with CTB (14).
Sublingual delivery of such a vaccine elicited a mucosal immune response to CTB and
provided passive protection against cholera challenge in an infant mouse model (8).
However, expression of R-CTB from the native chromosomal location of RbmA resulted
in decreased surface accumulation and poor immunogenicity. We hypothesized that a
mucosal adjuvant might bolster immunogenicity (15–17). Our goal in this study was to
incorporate a mucosal adjuvant into our antigen presentation platform. Both cholera
toxin (CT) and a detoxiﬁed form of cholera toxin, mmCT (i.e., multiply mutated CT), are
excellent mucosal adjuvants (18, 19). Both CT and mmCT have been shown to enhance
vaccine efﬁcacy by promoting differentiation and maturation of Th17 cells (20–22),
which closely correlates with production of mucosal IgA (23). Here we engineer our
vaccine platform to express mmCT after delivery to the sublingual mucosa. We show
that in vivo delivery of mmCT by a live attenuated vaccine elicits a robust mucosal
immune response to CTB and boosts the mucosal immune response to LPS. Coexpres-
sion of mmCT and an RbmA-CTB fusion does not improve the response to CTB but
rather results in dose-dependent tolerance. We conclude that mmCT synthesized in vivo
acts as a mucosal adjuvant for antigens presented by this live attenuated V. cholerae
antigen presentation platform, provided they are sufﬁciently different from mmCT.
RESULTS
A live attenuated vaccine expressing a chromosomally encoded R-CTB variant
elicits poor mucosal responses to both V. cholerae LPS and CTB. In our initial
experiments, we used a plasmid encoding RbmA fused to CTB (8). To adapt our vaccine
platform for safe delivery as a live attenuated vaccine, we moved the gene encoding
R-CTB from a plasmid to the native RbmA site of a V. cholerae strain lacking both the
entire CTX phage and tcpA, the major component of toxin-coregulated pilus (TCP)
(Fig. 1A; see Tables S1 and S2 in the supplemental material) (24). Additionally, we
introduced two R¡A mutations in RbmA at positions 116 and 234 (RΔ-CTB). These
mutations have previously been found to abrogate the rugose colony morphology (25).
We hypothesized that these mutations might reduce cell-cell interactions mediated by
RbmA and thus alter antigen delivery to immune cells. Indeed, we found that while
RΔ-CTB remained associated with the cell pellet (Fig. 1B), bioﬁlms formed under static
conditions overnight by a strain carrying RΔ-CTB were more easily dispersed by
agitation than a strain carrying wild-type R-CTB (see Fig. S1 in the supplemental
material). This strain accumulated approximately 6-fold less RΔ-CTB on its surface than
a strain that expresses CTB conjugated to wild-type RbmA encoded on a plasmid
(Fig. 1C).
We delivered this strain sublingually to mice with one booster. Blood and stool were
collected at the time points shown in Fig. 1D. While LPS-speciﬁc serum IgG and IgA
were detected, low levels of LPS-speciﬁc IgA in the stool suggested that the mucosal
immune response to LPS was poor (Fig. 1E). In addition, the systemic and mucosal
immune responses to CTB were measurable only after boosting (Fig. 1F). We conclude
that the vaccine strain carrying chromosomally encoded RΔ-CTB is poorly immuno-
genic compared with our previous observations of R-CTB expressed from a plasmid. We
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attribute this to decreased accumulation of RΔ-CTB on the cell surface. This led us to
consider antigen delivery in tandem with a mucosal adjuvant.
Immunization with an mmCT-producing vaccine results in a robust antibody
response to CTB and augments the LPS-speciﬁc IgA response. Cholera toxin (CT) is
an excellent but impractical mucosal adjuvant due to its toxicity. Recently, a multiply
mutated form of CT (mmCT) has been developed that retains adjuvanticity but has
greatly reduced toxicity (19). We hypothesized that mmCT might serve as an excellent
adjuvant for our vaccine. We introduced mmCT into the native lacZ site on the
V. cholerae chromosome, where expression is driven by the lacZ promoter (PlacZ::mmCT)
(Fig. 2A; see Table S3 in the supplemental material). Because the V. cholerae genome
does not encode LacI, this promoter is constitutive in V. cholerae. mmCT would be
FIG 1 Chromosomally expressed RΔ-CTB is poorly immunogenic. (A) Genotype of an O139 serotype
vaccine strain in which the entire CTX phage, including the recombination sites, as well as the tcpA gene,
has been deleted. Two R¡A mutations (R116A and R234A) were introduced into rbmA. CTB is genetically
coupled to the 3= end of rbmA and placed under the native rbmA promoter on the chromosome
(cRΔ-CTB). (B) Western analysis of CTB fused to the C-terminal end of wild-type RbmA (WT) or an RbmA
protein carrying the R116A and R234A point mutations (Δ) was detected in the V. cholerae cell pellet. (C)
Quantiﬁcation of cell-associated CTB in femtograms per cell when expressed from a plasmid or on the
chromosome. (D) Vaccination scheme for the live attenuated vaccine. Open triangles indicate vaccina-
tion. Arrows indicate blood and stool sample collection. (E) Nanograms of LPS-speciﬁc antibodies per
milliliter of serum or per microgram of total IgA in stool after immunization with a live attenuated vaccine
strain expressing cRΔ-CTB. (F) Nanograms of CTB-speciﬁc antibodies per milliliter of serum or per
microgram of total IgA in stool after immunization with a live attenuated vaccine strain expressing
cRΔ-CTB. Error bars in panel C denote standard deviation. For panel C, * indicates P  0.05 using
two-tailed, unpaired Student’s t test. For panels E and F, * indicates P 0.05 and **** indicates P 0.0001
using one-way ANOVA followed by Dunnett’s test for multiple comparisons. Horizontal bars mark the
mean. Each vaccination group included 10 mice.
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suboptimal as an adjuvant if in vivo expression reduced cell ﬁtness. However, we found
that constitutive production of mmCT did not impair V. cholerae growth (Fig. 2B). We
then established secretion of mmCT into the supernatant of bacteria cultured in
Luria-Bertani (LB) broth by Western blotting using rabbit sera raised against cholera
toxin (Fig. 2C). Using enzyme-linked immunosorbent assay (ELISA), we determined that
a 10-l volume of the cell-free supernatant from an overnight culture of the mmCT-
producing strain contained approximately 50 fmol of mmCT. Furthermore, after incu-
bation in phosphate-buffered saline (PBS) at room temperature for 30 min and 1 h, the
length of time we estimate that the vaccine persists in the murine sublingual space, we
measured approximately 3 fmol and 4.7 fmol of mmCT per 10-l volume, respectively
(Fig. 2D). Even after the 1-h incubation at room temperature in PBS, mmCT expression
delivered approximately 4 orders of magnitude less CTB than is delivered by chromo-
somal expression of RΔ-CTB and 8 orders of magnitude less CTB than the Dukoral
vaccine (Fig. 2E).
We administered the live attenuated vaccine expressing mmCT alone to mice via the
sublingual route (Fig. 3A and B). Sublingual immunization with the live attenuated
vaccine enhanced the mucosal immune response to LPS, which had not yet declined at
day 84 after the primary immunization (Fig. 3C; see Fig. S2 in the supplemental
material). Serum and mucosal immune responses to CTB were robust and also lasted for
several weeks but declined by day 84 (Fig. 3D).
Codelivery of mmCT and cR-CTB attenuates the immune response to CTB.
Given the adjuvant activity of mmCT, we questioned whether codelivery of chromo-
somally encoded cRΔ-CTB and mmCT might further improve the mucosal immune
response to CTB. To test this, we administered a vaccine expressing cRΔ-CTB and mmCT
on the chromosome to mice with one booster at day 35 (Fig. 4A and B). The combi-
nation of mmCT and cRΔ-CTB had a minimal effect on the immune response to LPS but
FIG 2 Characterization of mmCT as an in vivo antigen and adjuvant. (A) Genotype of an O139 serotype
vaccine strain in which the entire CTX phage, including the recombination sites, as well as the tcpA gene
has been deleted. The genes encoding mmCT (a cholera toxin variant carrying multiple mutations in the
A subunit of cholera toxin) are integrated in frame into the lacZ gene on the V. cholerae chromosome.
A ribosome-binding site is included at the 5= end of the sequence encoding mmCT, allowing the lacZ
promoter to drive transcription and translation of mmCT. (B) Constitutive production of mmCT in LB
medium does not affect bacterial ﬁtness as measured by growth over time. (C) Western blot analysis of
cell pellets and supernatants (Supt) after overnight LB broth culture of the vaccine strain noted in panel
A with or without mmCT. Rabbit sera raised against CT followed by secondary anti-rabbit antibody were
used for detection. (D) Quantiﬁcation of mmCT in the supernatant of an overnight culture in LB and after
incubation of the vaccine preparation in PBS. Vaccines were kept on ice for less than 1 h before
administration. (E) Quantiﬁcation of the amount of CTB delivered as R-CTB and as part of mmCT,
compared to the amount of puriﬁed CTB in Dukoral vaccine. The amount of CTB from supernatant mmCT
was measured after 1 h of incubation at 22°C in PBS.
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attenuated the systemic and mucosal immune responses to CTB compared with the
vaccine expressing only mmCT (Fig. 4C and D and Fig. S2). We hypothesized that this
might reﬂect the development of tolerance due to the amino acid sequence shared
between R-CTB and mmCT. To explore the impact of tolerance on the immune
response to LPS, we measured vibriocidal antibodies, which correlate with protection
against cholera. These were not signiﬁcantly different at days 56 and 180 postvaccina-
tion for vaccines expressing RΔ-CTB with or without mmCT (Fig. 4E) and were compa-
rable to the levels of vaccines previously demonstrated to confer protection against
V. cholerae (8). Furthermore, LPS-speciﬁc IgG1 and IgG2a titers were similar between the
two vaccines (Fig. 4F). To further conﬁrm that this represented a tolerance response
speciﬁcally to CTB, we assessed the impact of delivery of greater amounts of CTB
through expression of R-CTB from a plasmid along with constitutive expression of
chromosomally encoded mmCT (Fig. S3A). This vaccine was administered sublingually
to mice according to the schedule shown in Fig. S3B, with boosters administered on
days 14 and 28. Again, the immune response to LPS was similar to those of other
vaccines expressing mmCT (Fig. S3C). However, the immune response to CTB was
greatly attenuated (see Fig. S3D and S4 in the supplemental material). We conclude
that mmCT is not an ideal adjuvant for heterologous proteins that are highly similar to
cholera toxin, such as the heat-labile toxin of ETEC.
DISCUSSION
Adjuvanted vaccines that can be easily administered to prevent epidemic and
endemic diarrheal disease will greatly improve quality of life in resource-poor settings.
Our goal is to develop an antigen presentation platform that does not require puriﬁ-
cation of antigens or adjuvants. Here we describe the design of a live attenuated
FIG 3 In situ production of mmCT alone after sublingual vaccine delivery elicits a robust and long-lived immune response to CTB. (A) Genotype of vaccine strain
used. Expression of genes encoding mmCT is driven by the constitutive lacZ promoter on the chromosome of the vaccine strain. (B) Vaccination scheme for
the live attenuated vaccines with constitutive expression of mmCT. Open triangles indicate vaccination. Arrows indicate blood and stool sample collection. (C)
Nanograms of LPS-speciﬁc antibodies per milliliter of serum or per microgram of total IgA in stool after immunization with a live attenuated vaccine strain
expressing mmCT. (D) Nanograms of CTB-speciﬁc antibodies per milliliter of serum or per microgram of total IgA in stool after immunization with a live
attenuated vaccine strain expressing mmCT. *, P  0.05, **, P  0.01, ***, P  0.001, and ****, P  0.0001, using one-way ANOVA and Dunnett’s test. Horizontal
bars mark the mean. Each vaccination group included 10 mice.
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vaccine platform that is capable of synthesizing mmCT, its own mucosal adjuvant, in
vivo and can be delivered sublingually. mmCT improves the magnitude and longevity
of the mucosal immune response to V. cholerae LPS and elicits both systemic and
mucosal responses to CTB. However, inclusion of CTB as an antigen fused to the bioﬁlm
FIG 4 Coexpression of the adjuvant mmCT with chromosomal RΔ-CTB attenuates the immune response
to CTB. (A) Genotype of an O139 serotype vaccine strain in which the entire CTX phage, including the
recombination sites, as well as the tcpA gene has been deleted. Constitutive expression of genes
encoding mmCT is driven by the native, chromosomal lacZ promoter. CTB is genetically coupled to the
3= end of rbmA carrying R116A and R234A mutations and placed under the native rbmA promoter on the
chromosome (cRΔ-CTB). (B) Vaccination scheme for the live attenuated vaccine with chromosomal
RΔ-CTB and constitutive expression of mmCT. Open triangles indicate vaccination. Arrows indicate blood
and stool sample collection. (C and D) Nanograms of LPS-speciﬁc antibodies per milliliter of serum or
micrograms per total IgA in stool (C) and nanograms of CTB-speciﬁc antibodies per milliliter of serum or
per microgram of total IgA in stool (D) after immunization with a live attenuated vaccine strain
expressing cRΔ-CTB and mmCT. Data were log transformed prior to calculation of statistical signiﬁcance.
n.s., not signiﬁcant (P 0.05), *, P 0.05, **, P 0.01, ***, P 0.001, and ****, P 0.0001, using one-way
ANOVA and Dunnett’s multiple-comparison test. Horizontal bars mark the mean. Each vaccination group
included 10 mice. (E and F) Comparison of (E) vibriocidal titers and (F) LPS-speciﬁc IgG1 and IgG2a for
vaccines expressing cRΔ-CTB with or without mmCT at days 56 and 180. Differences were not statistically
signiﬁcant.
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matrix protein RbmA dampened the immune response to CTB in a dose-dependent
fashion. We hypothesize that this is an antigen-speciﬁc tolerance response that results
from the CTB peptide shared by R-CTB and mmCT. We conclude that while mmCT
synthesized in the sublingual space can improve the immunogenicity of sublingually
presented antigens, it is not an ideal adjuvant for antigens that are structurally similar
to cholera toxin.
Here we have delivered mmCT through constitutive synthesis by a live attenuated
vaccine administered via the sublingual route. The adjuvanticity of puriﬁed mmCT has
previously been demonstrated (18, 19). A mechanism is suggested by studies of the
double mutant LT (dmLT) adjuvant, an attenuated variant of the closely related
heat-labile toxin of enterotoxigenic E. coli. Puriﬁed dmLT was shown to have adjuvant
activity comparable to that of native cholera toxin when administered sublingually,
likely by promoting proliferation of speciﬁc Th1 and Th17 cells (26–28). Detoxiﬁed
cholera toxin derivatives have previously been incorporated into live attenuated
V. cholerae strains and delivered via the nares (29). Similar to the sublingual route, the
intranasal route of vaccine administration circumvents the requirement for passage
through the acidic environment of the stomach, but also has unique disadvantages.
Despite its documented safety in an oral formulation, intranasal administration of a
dmLT-adjuvanted inﬂuenza vaccine was correlated with onset of Bell’s palsy in healthy
adults (30–32). The safety of sublingually administered mmCT, which was developed as
an alternative to dmLT, has not been investigated in humans. Therefore, future work
will be necessary to establish the safety of mmCT in our current vaccine formulation.
The sublingual space is subject to frequent evacuations through deglutition. Nev-
ertheless, for ease of administration, we have chosen to deliver our vaccine via this
route. To increase residence time, thermoresponsive gels have developed for vaccine
delivery to the sublingual space. Such a gel, when used for sublingual delivery of an
inactivated polio vaccine combined with the adjuvant dmLT, improved production of
mucosal IgA and neutralizing antibodies (33). Our data suggest that, in the absence of
such a gel, our current live attenuated vaccine formulation induces robust systemic and
mucosal immune responses. V. cholerae has a propensity to attach to diverse surfaces
(34, 35). One advantage of our live attenuated vaccine vector may be its ability to attach
to and interact with the sublingual surface, thus resisting evacuation during deglutition.
Our ﬁndings warrant exploration of the interaction between our live attenuated vaccine
and the sublingual mucosa and the impact of depot technologies on immunogenicity.
Here, we have produced a sublingually administered, adjuvanted live attenuated
vaccine platform. This vaccine does not require additional preparation or protein
puriﬁcation, as the cholera toxin-based adjuvant is constitutively produced after ad-
ministration. Furthermore, it induces a robust mucosal IgA response to Vibrio cholerae
LPS and cholera toxin. This has implications for the development of future vaccines,
especially those based on live attenuated V. cholerae vector strains. This innovation has
the potential to simplify manufacturing and administration costs of vaccines effective
against diarrheal pathogens.
MATERIALS AND METHODS
Bacterial strains and culture conditions. Vibrio cholerae strains were cultured at 27°C in Luria-
Bertani (LB) broth supplemented with 100 g/ml streptomycin, with shaking at 200 rpm. Escherichia coli
was grown in LB broth at 37°C with shaking. Where necessary, plasmids were maintained with 100 g/ml
of ampicillin in the culture medium. Protein production from plasmid-borne Ptac was induced with
0.5 mM IPTG (-D-1-thiogalactopyranoside). Frozen stocks were maintained in 15% glycerol at 80°C.
Strains used in this study are listed in Table S1.
DNA manipulations and strain construction. All oligonucleotides were synthesized by Integrated
DNA Technologies, Inc., and are detailed in Tables S2 and S3. Restriction enzymes were purchased from
New England Biolabs (NEB) and used according to the manufacturer’s instructions. Gibson assembly of
DNA fragments was carried out with the NEBuilder Hi-Fi DNA assembly kit (NEB). PCRs were performed
with GoTaq polymerase (Promega) for screening and Q5 high-ﬁdelity polymerase (NEB) for cloning.
Genomic DNA from wild-type strain MO10, a V. cholerae O139 serotype strain, was used as the PCR
template unless otherwise noted.
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(i) Construction of vaccine strain harboring a deletion in tcpA. A sacB-encoding suicide vector
carrying a deletion construct for tcpA was introduced into MO10 ΔCTX by conjugation (36). Homolo-
gous recombination and positive deletion clone selection were carried out as described below.
(ii) Construction of vaccine strain expressing plasmid-encoded R-CTB. The previously described
pFLAG-CTC derivative carrying the gene encoding the B subunit of cholera toxin (CTB) fused to the gene
encoding wild-type RbmA (R-CTB) under an IPTG-inducible promoter was introduced into MO10 ΔCTX
ΔtcpA by electroporation (14). Protein production in positive transformants was veriﬁed by Western
blotting using an anti-CTB antibody as described below.
(iii) Construction of chromosomal R-CTB vaccine strain. The rbmA-ctxB sequence was ampliﬁed
from the pFLAG-CTC plasmid carrying R-CTB using the rbmA-RR primer series listed in Table S2. The two
point mutations R116A and R234A were introduced by incorporation into the ampliﬁcation primers.
Gibson assembly was used to ligate the fragments into XhoI-linearized suicide plasmid pWM91. Plasmids
from positive E. coli clones were isolated and conﬁrmed by sequencing. Homologous recombination into
the chromosomal rbmA gene of the MO10 ΔCTX ΔtcpA strain and positive clone selection were carried
out as described below.
(iv) Construction of PlacZ::mmCT in V. cholerae. The mmCT sequence was obtained by Gibson
assembly of PCR fragments ampliﬁed from genomic DNA, with the exception of the ﬁrst 97 bases, which
were ampliﬁed from an oligonucleotide synthesized to contain the proximal ribosome binding motif
from the Ptrc promoter and the ﬁrst 97 nucleotides of the ctxA gene (Table S3). Mutations of mmCT (19)
and stop codons distal to the ribosome binding site were introduced on primers (Table S2) and
conﬁrmed in the assembled product by sequencing. This was then ligated between two PCR fragments
of the lacZ gene by Gibson assembly to obtain the ﬁnal construct. This lacZ-mmCT construct was
digested using SacI and ligated into the sacB-encoding suicide plasmid pWM91. Plasmids from positive
E. coli clones were isolated, and the sequence of the inserted DNA was conﬁrmed by sequencing with
M13 primers. Homologous recombination into the MO10 ΔCTX ΔtcpA strain and positive clone selection
were carried out as previously described (37, 38).
Vaccine preparation. (i) Protein induction. Frozen stocks of strains carrying the plasmid encoding
R-CTB were inoculated into 3 ml of LB supplemented with streptomycin and ampicillin (LB-Sm/Amp) and
cultured at 27°C overnight. This starter culture was collected by centrifugation, washed once with
LB-Sm/Amp, and subcultured into 25 ml of fresh LB-Sm/Amp in a 250-ml ﬂask. After incubation for 6 to
8 h at 27°C with shaking, IPTG was added to a ﬁnal concentration of 0.5 mM, and the culture was
incubated for an additional 2 h at 27°C with shaking.
(ii) TCA precipitation of secreted proteins. Proteins secreted into the supernatant were precipi-
tated with trichloroacetic acid (TCA) and washed with acetone. Brieﬂy, spent supernatant was passed
through a 0.2-m-pore ﬁlter to remove bacterial cells. TCA was added to the cell-free supernatant to a
ﬁnal concentration of 10%, and the supernatant was incubated overnight at 4°C with gentle mixing.
Precipitated proteins were collected by centrifugation and washed three times with ice-cold acetone.
Residual acetone was evaporated by brief incubation at 95°C. The protein pellet was resuspended in 4
Laemmli buffer containing -mercaptoethanol and prepared for Western blotting as described below.
(iii) Preparation of whole-cell vaccines. After protein induction for strains carrying pR-CTB or after
overnight culture for the strains encoding chromosomal RΔ-CTB vaccine constructs, the bacterial culture
was centrifuged at 5,000  g for 15 min at 4°C to collect cells. The supernatant was passed through a
0.2-m-pore ﬁlter, and the resulting cell-free supernatant was used for TCA precipitation and Western
blot analysis. The remaining bacterial pellet was washed three times with 12 ml of sterile PBS and ﬁnally
resuspended in 1 ml of PBS. This constituted the live attenuated whole-cell vaccine. For each vaccine
preparation, 10 l was removed to quantify colony-forming units (CFU), and 20 l was reserved for
Western blot analysis. For each immunization, vaccines expressing mmCT were kept on ice for less than
1 h before administration, and all vaccines were used within 2 h of preparation. Each vaccine dose
consisted of 108 to 109 cells in 10 l.
(iv) Western blot analysis. Supernatants and cell pellet samples were separated by centrifugation.
TCA precipitation of the supernatant was performed prior to detection of mmCT. These samples were
combined with 4 Laemmli buffer containing -mercaptoethanol, sonicated in an ice bath, boiled for
5 min, and brieﬂy centrifuged to remove particulates. Proteins were resolved on a denaturing 4 to 20%
gradient Tris-HCl gel and then transferred onto a polyvinylidene diﬂuoride membrane by semidry
transfer (BioRad). The membrane was blocked in Tris-buffered saline with 0.1% Tween (TBST) and 5%
skim milk for 2 h at room temperature with gentle shaking. Fresh blocking solution containing primary
antibody was added in a 1:1,000 dilution. Rabbit-derived serum raised against both the A and B subunits
of cholera toxin (Sigma) was used to detect mmCT. After overnight incubation with primary antibodies,
the membrane was washed 3 times with TBST. Membranes were then incubated for 2 h at room
temperature with 1:5,000-diluted HRP-conjugated anti-rabbit secondary antibody (Cell Signaling) and
developed using an ECL (enhanced chemiluminescence) Western blotting substrate (Pierce).
(v) Quantiﬁcation of R-CTB and R-CTB by densitometry. Known concentrations of puriﬁed CTB
(List Laboratories) were resolved by SDS-PAGE alongside R-CTB or RΔ-CTB samples (plasmid and
chromosomal) and used as standards for quantiﬁcation. ImageJ was used to generate a standard curve
ﬁtted to the intensities of bands corresponding to the CTB standards. The concentrations of R-CTB and
RΔ-CTB were calculated using the linear portion of the standard curve.
(vi) Quantiﬁcation of mmCT in supernatants by ELISA. The amount of mmCT secreted into the
supernatant by the live vaccine suspension was quantiﬁed by GM1 ELISA as previously described (39).
The supernatant of a wild-type strain that does not express mmCT was similarly prepared and used as
a negative control.
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One hundred nanograms of bovine monosialoganglioside GM1 (Sigma) in sodium carbonate buffer
was added to each well of a 96-well microtiter plate (Nunc, Maxisorp), incubated overnight at room
temperature, and then washed in PBS-Tween (PBST). Serial dilutions of cell-free supernatants in PBS were
applied to GM1-coated wells. Puriﬁed CTB was prepared in a 1-g/ml concentration in PBS, and serial
dilutions were also applied to GM1-coated wells to generate a standard curve. The plates were incubated
overnight at room temperature, washed in PBST, and blocked in PBS-bovine serum albumin (BSA).
Monoclonal anti-CTB IgG (Fisher no. PIMA183519) diluted to 1 g/ml in PBST-BSA was added to the
plates, and the mixture was incubated overnight. The plates were probed with HRP-conjugated goat
anti-mouse antibodies (Bethyl Laboratories) and developed with Turbo 1-Step TMB (Thermo Fisher) as
described below.
Immunization and sample collection. (i) Animals. Female 6- to 8-week-old BALB/c mice were used
in all immunization experiments. Mice were purchased from Charles River Laboratories, Inc., and housed
in a biosafety level 2 facility at Boston Children’s Hospital with food and water ad libitum. Mice were
acclimatized for 5 days. All procedures had been previously approved by the Institutional Animal Care
and Use Committee.
(ii) Sublingual administration of live attenuated vaccine. Mice were anesthetized by intraperito-
neal injection with a cocktail of ketamine (100 mg/kg body weight) and xylazine (10 mg/kg) and then
held upright, while 10 l of the vaccine was delivered under the tongue by a micropipette directed
toward the ﬂoor of the mouth. Mice were maintained in the upright position for 2 min before resting,
ventral side down, for at least 30 min until regaining consciousness.
(iii) Collection of blood and stool samples. Blood and stool samples were collected 1 day before
vaccination and at the designated time points throughout the study period. Fresh stool pellets were
frozen at 80°C until use. Blood was collected from the tail vein using capillary tubes with clot activator
(Sarstedt). Sera were obtained by clearing the clotted blood with centrifugation at 10,000  g for 5 min
at room temperature and stored at 20°C. Stool samples were prepared as previously described (40).
Brieﬂy, pellets were thawed on ice, transferred to 15-ml conical tubes containing 3 ml of chilled
resuspension solution (0.1 mg/ml soybean trypsin inhibitor and a 3:1 mixture of PBS to 0.1 M EDTA),
thoroughly homogenized, and centrifuged at 650  g for 10 min at room temperature. The supernatant
was collected and centrifuged once more at 15,300  g for 10 min at 4°C. Phenylmethylsulfonyl ﬂuoride
(PMSF) was added to the supernatant to a ﬁnal concentration of 2 mM. Stool samples were kept at20°C
or at 80°C for long-term storage.
Enzyme-linked immunosorbent assays. (i) Quantiﬁcation of CTB-speciﬁc antibodies by ELISA.
Standard curve. CTB-speciﬁc IgA was not available for use in a standard curve. Therefore, to assess
linearity, standard curves were generated by capturing IgA and IgG in reference mouse serum with goat
anti-mouse IgG or IgA. Microtiter plate wells were incubated overnight with 100 g of goat anti-mouse
IgG or IgA diluted in sodium carbonate buffer. The wells were washed in PBST and blocked with PBS-BSA.
Reference mouse serum (Bethyl) was diluted to 1 g/ml of total IgG or IgA and applied to the wells. The
wells were washed after overnight incubation and then probed with HRP-conjugated goat anti-mouse
antibodies and developed as described above for quantiﬁcation of mmCT.
Test samples. Microtiter plates were coated with GM1 followed by puriﬁed CTB as described above.
The plates were blocked in PBS-BSA and washed in PBST. Serially diluted sera or stool samples were
applied to the wells and incubated overnight. Serum dilutions ranged from 1:50 to 1:6,400, and stool
dilutions ranged from 1:2 to 1:128. The plates were probed and developed as described above. In
addition, antigen-speciﬁc IgG1 and IgG2a antibodies were captured as described above and then
detected with HRP-conjugated anti-IgG1 (Bethyl no. A90-105P) or anti-IgG2a (Bethyl no. A90-107P)
antibodies.
Instruments and data analysis. Antigen-speciﬁc total IgA and IgG as well as total stool IgA were
measured on a BioRad Benchmark Plus plate reader using a kinetic protocol and then analyzed using the
built-in microplate Manager software (v5.2.1). LPS-speciﬁc serum IgG1 and IgG2a were measured on a
Tecan Sunrise plate reader using a kinetic protocol and analyzed with the associated Magellan software
(v7.2).
(ii) Quantiﬁcation of total stool IgA by ELISA. Total fecal IgA was used to normalize antigen-
speciﬁc IgA in the stool. Each well of a microtiter plate was coated with 100 ng of goat anti-mouse IgA
antibody in sodium bicarbonate buffer and incubated overnight. Plates were washed in PBST and
blocked in PBS-BSA. Stool samples were serially diluted from 1:200 to 1:25,600 in PBST-BSA and added
to the plates. The plates were incubated overnight and then probed and developed as described above.
Standard curves were generated as described for CTB/LTB-speciﬁc antibodies.
(iii) LPS extraction and measurement of O-antigen-speciﬁc antibodies. LPS was extracted from
50 ml of a V. cholerae MO10 (serotype O139) overnight culture using a commercial kit (Bulldog Bio).
Serum and stool antibodies recognizing the O1 or O139 serotypes were quantiﬁed as previously
described (41). A 1:1,000 dilution of LPS in sodium carbonate buffer was applied to microtiter plates and
incubated overnight. The plates were washed in PBST and blocked for 40 min at 37°C in PBS-BSA. Serum
and stool samples were applied to the plates in dilutions similar to those used to measure CTB-speciﬁc
antibodies. The plates were incubated for 90 min at 37°C and then washed in PBST. Plates were
incubated for 90 min at 37°C after addition of 100 ng of HRP-conjugated goat anti-mouse antibodies per
well. Plates were developed using the same protocol described for quantiﬁcation of CTB-speciﬁc
antibodies.
Vibriocidal antibody titers. Serum vibriocidal antibody titers were determined as previously
described with the following modiﬁcation (42). Mouse sera collected prior to and on the indicated days
after immunization were incubated at 56°C for 1 h to inactivate endogenous complement, serially diluted
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2-fold in PBS in 0.5-l tubes, and then kept on ice until use. Wild-type MO10 was grown to mid-
logarithmic phase in brain heart infusion (BHI) broth containing 100 g/ml streptomycin and diluted in
PBS containing 20% guinea pig complement to 4 106 CFU/ml. An equal volume of this suspension was
added to the serum dilutions to obtain a ﬁnal concentration of 10% complement and 2  106 CFU/ml
V. cholerae, and the mixture was incubated for 1 h at 37°C. Five microliters of this mixture was inoculated
into wells of a 384-well microtiter plate containing 35 l of BHI with streptomycin and incubated at 37°C
for 4 h. At this point, growth was assessed by measuring the optical density at 600 nm (OD600). The
reciprocal of the highest serum dilution at which the OD600 remained below the level of detection was
noted as the bactericidal titer.
Ethics statement. Animal experiments were performed in accordance with standards outlined in the
National Research Council’s Guide for the Care and Use of Laboratory Animals and Boston Children’s
Hospital’s Public Health Service-approved Animal Welfare Assurance. The protocol was approved by the
Boston Children’s Hospital Institutional Animal Care and Use Committee (IACUC) appointed to review
proposals for research involving vertebrate animals.
Statistical analysis. Statistical analyses were performed in GraphPad Prism 7. One-way ordinary
analysis of variance (ANOVA) with Dunnett’s test was used for multiple comparisons. A two-tailed,
unpaired Student’s t test was used for pairwise comparisons. All vaccine groups consisted of 10 mice.
Error bars indicate standard deviations unless otherwise noted. Western blots and photographic images
are representative of experimental triplicates.
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